Early CMV-replication after allogeneic stem cell transplantation is associated with a reduced relapse risk in lymphoma

References

• Boeckh M, Nichols WG. Immunosuppressive effects of beta-herpesviruses. Herpes. 2003;10:12–16.
   PubMedGoogle Scholar
• Boeckh M, Nichols WG, Papanicolaou G, et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003;9:543–558.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Gooley TA, Myerson D, et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88:4063–4071.
   PubMed Web of Science ®Google Scholar
• Meyer-König U, Hufert FT, von Laer DM. Infection of blood and bone marrow cells with the human cytomegalovirus in vivo. Leuk Lymphoma. 1997;25:445–454.
   PubMed Web of Science ®Google Scholar
• Sinclair J, Reeves M. The intimate relationship between human cytomegalovirus and the dendritic cell lineage. Front Microbiol. 2014;5:389.
   PubMed Web of Science ®Google Scholar
• Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 1995;86:2815–2820.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood. 2004;103:2003–2008.
   PubMed Web of Science ®Google Scholar
• Nichols WG, Corey L, Gooley T, et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis. 2002;185:273–282.
   PubMed Web of Science ®Google Scholar
• Elmaagacli AH, Steckel NK, Koldehoff M, et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood. 2011;118:1402–1412.
   PubMed Web of Science ®Google Scholar
• Craddock C, Labopin M, Pillai S, et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukemia. Leukemia. 2011;25:808–813.
   PubMed Web of Science ®Google Scholar
• Behrendt CE, Rosenthal J, Bolotin E, et al. Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy. Biol Blood Marrow Transplant. 2009;15:54–60.
   PubMed Web of Science ®Google Scholar
• Erlach KC, Podlech J, Rojan A, et al. Tumor control in a model of bone marrow transplantation and acute liver-infiltrating B-cell lymphoma: an unpredicted novel function of cytomegalovirus. J Virol. 2002;76:2857–2870.
   PubMed Web of Science ®Google Scholar
• Erlach KC, Böhm V, Seckert CK, et al. Lymphoma cell apoptosis in the liver induced by distant murine cytomegalovirus infection. J Virol. 2006;80:4801–4819.
   PubMed Web of Science ®Google Scholar
• Mariotti J, Maura F, Spina F, et al. Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20:885–890.
   PubMedGoogle Scholar
• Green ML, Leisenring WM, Xie H, et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood. 2013;122:1316–1324.
   PubMed Web of Science ®Google Scholar
• Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127:2427–2438.
   PubMed Web of Science ®Google Scholar
• Koldehoff M, Lindemann M, Opalka B, et al. Cytomegalovirus induces apoptosis in acute leukemia cells as a virus-versus-leukemia function. Leuk Lymphoma. 2015;56:3189–3197.
   PubMed Web of Science ®Google Scholar
• Ottinger HD, Ferencik S, Beelen DW, et al. Hematopoietic stem cell transplantation: contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched related donors, and HLA-matched unrelated donors. Blood. 2003;102:1131–1137.
   PubMed Web of Science ®Google Scholar
• Gratwohl A. Principles of conditioning. In: Apperley J, Carreras E, Gluckman E, et al., editors. The ESH-EBMT handbook on haematopoietic stem cell transplantation. 2008. Chapter 6; pp. 128–144.
   Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
   PubMed Web of Science ®Google Scholar
• Trenschel R, Ross S, Hüsing J, et al. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT. Bone Marrow Transplant. 2000;25:665–672.
   PubMed Web of Science ®Google Scholar
• Gimeno C, Solano C, Latorre JC, et al. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J Clin Microbiol. 2008;46:3311–3318.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, International Harmonization Project on Lymphoma, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304.
   PubMed Web of Science ®Google Scholar
• Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation (second of two parts). N Engl J Med. 1975;292:895–902.
   PubMed Web of Science ®Google Scholar
• Beelen DW, Elmaagacli A, Müller KD, et al. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood. 1999;93:3267–3275.
   PubMed Web of Science ®Google Scholar
• Beelen DW, Quabeck K, Kaiser B, et al. Six weeks of continuous intravenous cyclosporine and short-course methotrexate as prophylaxis for acute graft-versus-host disease after allogeneic bone marrow transplantation. Transplantation. 1990;50:421–427.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.
   Web of Science ®Google Scholar
• Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706.
   PubMed Web of Science ®Google Scholar
• Cheng SC, Fine JP, Wei LJ. Prediction of cumulative incidence function under the proportional hazards model. Biometrics. 1998;54:219–228.
   PubMed Web of Science ®Google Scholar
• Cox DR. Regression models and life-tables (with discussion). J Royal Stat Soc. 1972;B34:187–220.
   Google Scholar
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–2919.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48:452–458.
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Stern M, Brand R, et al. for the European Group for Blood and Marrow Transplantation and the European Leukemia Net. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer. 2009;115:4715–4726.
   PubMed Web of Science ®Google Scholar
• Elmaagacli AH, Koldehoff M. Cytomegalovirus replication reduces the relapse incidence in patients with acute myeloid leukemia. Blood. 2016;128:456–459.
   PubMed Web of Science ®Google Scholar
• Pourgheysari B, Piper KP, McLarnon A, et al. Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT. Bone Marrow Transplant. 2009;43:853–861.
   PubMed Web of Science ®Google Scholar
• Foley B, Cooley S, Verneris MR, et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C + natural killer cells with potent function. Blood. 2012;119:2665–2674.
   PubMed Web of Science ®Google Scholar
• Scheper W, van Dorp S, Kersting S, et al. γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia. Leukemia. 2013;27:1328–1338.
   PubMed Web of Science ®Google Scholar
• Cichocki F, Cooley S, Davis Z, et al. CD56dimCD57 + NKG2C + NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. Leukemia. 2016;30:456–463.
   PubMed Web of Science ®Google Scholar
• Horowitz A, Guethlein LA, Nemat-Gorgani N, et al. Regulation of adaptive NK cells and CD8 T cells by HLA-C correlates with allogeneic hematopoietic cell transplantation and with cytomegalovirus reactivation. J Immunol. 2015;195:4524–4536.
   PubMed Web of Science ®Google Scholar
• Stauch D, Dernier A, Sarmiento Marchese E, et al. Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificity. PLoS One. 2009;4:e4709.
   Web of Science ®Google Scholar
• Elmaagacli AH, Koldehoff M, Lindemann M, et al. Response: T cells are required for the CMV-induced antileukemia effect after transplant. Blood. 2012;119:1090–1091.
   Web of Science ®Google Scholar
• Thomson KJ, Mackinnon S, Peggs KS. CMV-specific cellular therapy for acute myeloid leukemia? Blood. 2012;119:1088–1090.
   PubMed Web of Science ®Google Scholar
• Fletcher JM, Prentice HG, Grundy JE. Natural killer cell lysis of cytomegalo-virus (CMV)-infected cells correlates with virally induced changes in cell surface lymphocyte function-associated antigen-3 (LFA-3) expression and not with the CMV-induced down-regulation of cell surface class I HLA1. J Immunol. 1998;161:2365–2374.
   PubMed Web of Science ®Google Scholar
• Erard V, Guthrie KA, Riddell S, et al. Impact of HLA A2 and cytomegalovirus serostatus on outcomes in patients with leukemia following matched-sibling myeloablative allogeneic hematopoietic cell transplantation. Haematologica. 2006;91:1377–1383.
   PubMed Web of Science ®Google Scholar